Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.17 HKD | -2.50% | -11.36% | +11.43% |
Mar. 26 | Dawnrays Pharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 June 2024 | CI |
Mar. 25 | Dawnrays' 2023 Profit Falls 9% on Lower Revenue | MT |
Sales 2021 | 1.17B 161M 1.26B | Sales 2022 | 1.28B 177M 1.38B | Capitalization | 1.76B 244M 1.91B |
---|---|---|---|---|---|
Net income 2021 | 358M 49.53M 388M | Net income 2022 | 358M 49.53M 388M | EV / Sales 2021 | 1.06 x |
Net cash position 2021 | 807M 112M 873M | Net cash position 2022 | 1.07B 148M 1.16B | EV / Sales 2022 | 0.54 x |
P/E ratio 2021 |
5.73
x | P/E ratio 2022 |
4.93
x | Employees | 1,143 |
Yield 2021 |
4.79% | Yield 2022 |
6.63% | Free-Float | 39.99% |
1 day | -2.50% | ||
1 week | -11.36% | ||
Current month | -0.85% | ||
1 month | -1.68% | ||
3 months | +13.59% | ||
6 months | +4.46% | ||
Current year | +11.43% |
Managers | Title | Age | Since |
---|---|---|---|
Wei Xian Wu
CEO | Chief Executive Officer | 55 | 22-02-15 |
Yi jun Wu
DFI | Director of Finance/CFO | 59 | 02-11-30 |
Kei Ling Li
CHM | Chairman | 75 | 02-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kei Ling Li
CHM | Chairman | 75 | 02-09-30 |
Yung Lai Hung
BRD | Director/Board Member | 79 | 02-09-30 |
Hong Man Leung
BRD | Director/Board Member | 49 | 05-10-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 1.17 | -2.50% | 740 000 |
24-03-27 | 1.2 | +2.56% | 388,000 |
24-03-26 | 1.17 | -0.85% | 474,000 |
24-03-25 | 1.18 | -10.61% | 2,790,000 |
24-03-22 | 1.32 | 0.00% | 434,000 |
Delayed Quote Hong Kong S.E., March 28, 2024 at 04:08 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+11.43% | 230M | |
+33.50% | 701B | |
+26.24% | 571B | |
+0.78% | 381B | |
+20.85% | 334B | |
+16.38% | 319B | |
+2.72% | 210B | |
+0.98% | 210B | |
-6.77% | 201B | |
-3.51% | 157B |